These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 28278374)

  • 1. Oral Gavage Delivery of PR8 Antigen with β-Glucan-Conjugated GRGDS Carrier to Enhance M-Cell Targeting Ability and Induce Immunity.
    Lee DY; Nurunnabi M; Kang SH; Nafiujjaman M; Huh KM; Lee YK; Kim YC
    Biomacromolecules; 2017 Apr; 18(4):1172-1179. PubMed ID: 28278374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-glucan microparticles targeted to epithelial APN as oral antigen delivery system.
    Baert K; de Geest BG; de Rycke R; da Fonseca Antunes AB; de Greve H; Cox E; Devriendt B
    J Control Release; 2015 Dec; 220(Pt A):149-159. PubMed ID: 26485047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-Glucan microparticles are good candidates for mucosal antigen delivery in oral vaccination.
    De Smet R; Demoor T; Verschuere S; Dullaers M; Ostroff GR; Leclercq G; Allais L; Pilette C; Dierendonck M; De Geest BG; Cuvelier CA
    J Control Release; 2013 Dec; 172(3):671-8. PubMed ID: 24041710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conjugating influenza a (H1N1) antigen to n-trimethylaminoethylmethacrylate chitosan nanoparticles improves the immunogenicity of the antigen after nasal administration.
    Liu Q; Zheng X; Zhang C; Shao X; Zhang X; Zhang Q; Jiang X
    J Med Virol; 2015 Nov; 87(11):1807-15. PubMed ID: 25959372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conjugation of β-glucan markedly increase the immunogencity of meningococcal group Y polysaccharide conjugate vaccine.
    Qiao W; Ji S; Zhao Y; Hu T
    Vaccine; 2015 Apr; 33(17):2066-72. PubMed ID: 25728319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functionalized nanoscale β-1,3-glucan to improve Her2+ breast cancer therapy: In vitro and in vivo study.
    Nasrollahi Z; Mohammadi SR; Mollarazi E; Yadegari MH; Hassan ZM; Talaei F; Dinarvand R; Akbari H; Atyabi F
    J Control Release; 2015 Mar; 202():49-56. PubMed ID: 25597638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination.
    Slütter B; Plapied L; Fievez V; Sande MA; des Rieux A; Schneider YJ; Van Riet E; Jiskoot W; Préat V
    J Control Release; 2009 Sep; 138(2):113-21. PubMed ID: 19445980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances and Potential Applications of Chitosan Nanoparticles as a Delivery Carrier for the Mucosal Immunity of Vaccine.
    Li D; Fu D; Kang H; Rong G; Jin Z; Wang X; Zhao K
    Curr Drug Deliv; 2017; 14(1):27-35. PubMed ID: 27494157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational Design of Adjuvant for Skin Delivery: Conjugation of Synthetic β-Glucan Dectin-1 Agonist to Protein Antigen.
    Donadei A; Gallorini S; Berti F; O'Hagan DT; Adamo R; Baudner BC
    Mol Pharm; 2015 May; 12(5):1662-72. PubMed ID: 25867449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells.
    Abdel-Motal UM; Guay HM; Wigglesworth K; Welsh RM; Galili U
    J Virol; 2007 Sep; 81(17):9131-41. PubMed ID: 17609270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-Glucan as an immune activator and a carrier in the construction of a synthetic MUC1 vaccine.
    Wang H; Yang B; Wang Y; Liu F; Fernández-Tejada A; Dong S
    Chem Commun (Camb); 2018 Dec; 55(2):253-256. PubMed ID: 30534737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bile acid linked β-glucan nanoparticles for liver specific oral delivery of biologics.
    Chowdhury AS; Geetha Bai R; Islam T; Abir M; Narayan M; Khatun Z; Nurunnabi M
    Biomater Sci; 2022 May; 10(11):2929-2939. PubMed ID: 35471198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination.
    Garinot M; Fiévez V; Pourcelle V; Stoffelbach F; des Rieux A; Plapied L; Theate I; Freichels H; Jérôme C; Marchand-Brynaert J; Schneider YJ; Préat V
    J Control Release; 2007 Jul; 120(3):195-204. PubMed ID: 17586081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conjugation of protein antigen to microparticulate beta-glucan from Saccharomyces cerevisiae: a new adjuvant for intradermal and oral immunizations.
    Berner VK; Sura ME; Hunter KW
    Appl Microbiol Biotechnol; 2008 Oct; 80(6):1053-61. PubMed ID: 18677470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deoxycholic acid modified-carboxymethyl curdlan conjugate as a novel carrier of epirubicin: in vitro and in vivo studies.
    Gao F; Li L; Zhang H; Yang W; Chen H; Zhou J; Zhou Z; Wang Y; Cai Y; Li X; Liu L; Zhang Q
    Int J Pharm; 2010 Jun; 392(1-2):254-60. PubMed ID: 20347028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designing oral vaccines targeting intestinal dendritic cells.
    Devriendt B; De Geest BG; Cox E
    Expert Opin Drug Deliv; 2011 Apr; 8(4):467-83. PubMed ID: 21375470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C5a receptor-targeting ligand-mediated delivery of dengue virus antigen to M cells evokes antigen-specific systemic and mucosal immune responses in oral immunization.
    Kim SH; Yang IY; Jang SH; Kim J; Truong TT; Van Pham T; Truong NU; Lee KY; Jang YS
    Microbes Infect; 2013 Nov; 15(13):895-902. PubMed ID: 23892099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination.
    Fievez V; Plapied L; des Rieux A; Pourcelle V; Freichels H; Wascotte V; Vanderhaeghen ML; Jerôme C; Vanderplasschen A; Marchand-Brynaert J; Schneider YJ; Préat V
    Eur J Pharm Biopharm; 2009 Sep; 73(1):16-24. PubMed ID: 19409989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymer nanomicelles for efficient mucus delivery and antigen-specific high mucosal immunity.
    Noh YW; Hong JH; Shim SM; Park HS; Bae HH; Ryu EK; Hwang JH; Lee CH; Cho SH; Sung MH; Poo H; Lim YT
    Angew Chem Int Ed Engl; 2013 Jul; 52(30):7684-9. PubMed ID: 23765547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of an M-cell-targeting ligand for oral vaccination induces efficient systemic and mucosal immune responses against a viral antigen.
    Kim SH; Jung DI; Yang IY; Jang SH; Kim J; Truong TT; Pham TV; Truong NU; Lee KY; Jang YS
    Int Immunol; 2013 Nov; 25(11):623-32. PubMed ID: 23900425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.